Across TCGA pan-cancer cohorts, DAPL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DAPL1 data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher DAPL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DAPL1 expression acts as an unfavorable survival marker.
SARC and LGG are the cancer types where DAPL1 Mutation most reproducibly stratifies survival.